85259-33-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-bromo-2-(4-nitrophenyl)acetate is utilized as a key intermediate for the production of anti-inflammatory drugs. Its unique structure allows for the development of compounds that can effectively target and alleviate inflammation.
Used in Agrochemical Production:
In the agrochemical industry, methyl 2-bromo-2-(4-nitrophenyl)acetate serves as a crucial building block for the synthesis of fungicides and insecticides. Its chemical properties enable the creation of effective agents that protect crops from pests and diseases, thereby ensuring agricultural productivity.
Used in Organic Synthesis:
Methyl 2-bromo-2-(4-nitrophenyl)acetate is employed as a versatile reagent in organic synthesis for the introduction of functional groups into complex molecular structures. This capability is essential for the development of new and innovative chemical compounds with diverse applications across various industries.

InChI:InChI=1/C9H8BrNO4/c1-15-9(12)8(10)6-2-4-7(5-3-6)11(13)14/h2-5,8H,1H3

Upstream product

• 67-56-1 methanol 
• 75288-21-0 2-bromo-2-(4-nitrophenyl)acetyl chloride 
• 2945-08-6 methyl (4-nitrophenyl)acetate 
• 104-03-0 4-nitrobenzeneacetic acid 
• 50434-36-1 4-nitrophenylacetyl chloride 

Downstream Products

• 85259-05-8 2-Imino-5-(4-nitro-phenyl)-thiazolidin-4-one; hydrobromide 
• 29704-42-5 4-nitromandelic acid methyl ester acetate 
• 783362-54-9 (5-acetylamino-5-{4-[(2-{2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-ethylcarbamoyl)-hydroxy-methyl]-phenylcarbamoyl}-pentyl)-carbamic acid tert-butyl ester 
• 783362-66-3 (5-acetylamino-5-{4-[(2-{2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-ethylcarbamoyl)-fluoro-methyl]-phenylcarbamoyl}-pentyl)-carbamic acid tert-butyl ester 
• 783362-63-0 4-acetylamino-4-{4-[(2-{2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-ethylcarbamoyl)-fluoro-methyl]-phenylcarbamoyl}-butyric acid tert-butyl ester 
• 783362-60-7 {2-[2-(2-{2-[4-(2-acetylamino-3-phenyl-propionylamino)-phenyl]-2-fluoro-acetylamino}-ethoxy)-ethoxy]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 783362-48-1 {2-[2-(2-{2-[4-(2-acetylamino-3-phenyl-propionylamino)-phenyl]-2-hydroxy-acetylamino}-ethoxy)-ethoxy]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 783362-20-9 {4-[Fmoc-Lys(Boc)amino]phenyl}-hydroxy-acetic acid methyl ester 

Relevant academic research and scientific papers

NAMPT MODULATORS

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

Rational design of novel irreversible inhibitors for human arginase

Parasites have developed a variety of strategies for invading hosts and escaping their immune response. A common mechanism by which parasites escape nitric oxide (NO) toxicity is the activation of host arginase. This activation leads to a depletion of L-arginine, which is the substrate for NO synthase, resulting in lower levels of NO and increased production of polyamines that are necessary for parasite growth and differentiation. For this reason, small molecule inhibitors for arginase show promise as new anti-parasitic chemotherapeutics. However, few arginase inhibitors have been reported. Here, we describe the discovery of novel irreversible arginase inhibitors, and their characterization using biochemical, kinetic, and structural studies. Importantly, we determined the site on human arginase that is labeled by one of the small molecule inhibitors. The tandem mass spectra data show that the inhibitor occupies the enzyme active site and forms a covalent bond with Thr135 of arginase. These findings pave the way for the development of more potent and selective irreversible arginase inhibitors.

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but wi

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Synthesis of Quinolines by Visible-Light Induced Radical Reaction of Vinyl Azides and α-Carbonyl Benzyl Bromides

A visible-light induced radical reaction of vinyl azides and α-carbonyl benzyl bromides was developed, which provides an efficient route to polysubstituted quinolines via a C-C and C-N bond formation sequence.

Chemoselective reduction and self-immolation based FRET probes for detecting hydrogen sulfide in solution and in cells

Hydrogen sulfide (H2S) has been regarded as the third gaseous transmitter. Based on the mechanism of chemoselective azido reduction and self-immolation, five fluorescence resonance energy transfer (FRET) probes for the detection of H2S were designed and synthesized. The effect of functional substitution of the self-immolative moiety on azido reduction and quinone-methide rearrangement were investigated. Their fluorescence responses and chemoselectivity for H2S detection were evaluated in solutions and in cells. This strategy may provide a general route for designing H 2S probes with many commercially available FRET pairs. the Partner Organisations 2014.

CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are de

SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS

Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients. are de

Developing novel activity-based fluorescent probes that target different classes of proteases.

In this article, we report the design and synthesis of a group of novel activity-based probes that target different protease sub-classes based on their substrate specificities, rather than their enzymatic mechanisms. The feasibility of our approach has be